Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.01
TBIO's Cash-to-Debt is ranked lower than
99% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.86 vs. TBIO: 0.01 )
Ranked among companies with meaningful Cash-to-Debt only.
TBIO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 1.59 Max: No Debt
Current: 0.01
Equity-to-Asset -8.58
TBIO's Equity-to-Asset is ranked lower than
100% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. TBIO: -8.58 )
Ranked among companies with meaningful Equity-to-Asset only.
TBIO' s Equity-to-Asset Range Over the Past 10 Years
Min: -8.58  Med: 0.68 Max: 0.95
Current: -8.58
-8.58
0.95
Piotroski F-Score: 3
Altman Z-Score: -169.79
Beneish M-Score: -51.01
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -624.98
TBIO's Operating Margin % is ranked lower than
92% of the 166 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. TBIO: -624.98 )
Ranked among companies with meaningful Operating Margin % only.
TBIO' s Operating Margin % Range Over the Past 10 Years
Min: -852.34  Med: -16.18 Max: -1.53
Current: -624.98
-852.34
-1.53
Net Margin % -1920.69
TBIO's Net Margin % is ranked lower than
96% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. TBIO: -1920.69 )
Ranked among companies with meaningful Net Margin % only.
TBIO' s Net Margin % Range Over the Past 10 Years
Min: -1993.59  Med: -21.04 Max: -2.06
Current: -1920.69
-1993.59
-2.06
ROA % -335.60
TBIO's ROA % is ranked lower than
97% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. TBIO: -335.60 )
Ranked among companies with meaningful ROA % only.
TBIO' s ROA % Range Over the Past 10 Years
Min: -335.6  Med: -18.86 Max: -2.7
Current: -335.6
-335.6
-2.7
ROC (Joel Greenblatt) % -898.92
TBIO's ROC (Joel Greenblatt) % is ranked lower than
82% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. TBIO: -898.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TBIO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -898.92  Med: -53.3 Max: -4.92
Current: -898.92
-898.92
-4.92
3-Year Revenue Growth Rate -70.90
TBIO's 3-Year Revenue Growth Rate is ranked lower than
96% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. TBIO: -70.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TBIO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -72.3  Med: -12.1 Max: 9.9
Current: -70.9
-72.3
9.9
3-Year EBITDA Growth Rate -6.50
TBIO's 3-Year EBITDA Growth Rate is ranked lower than
66% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. TBIO: -6.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TBIO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -55  Med: 0.5 Max: 84.6
Current: -6.5
-55
84.6
3-Year EPS without NRI Growth Rate -15.70
TBIO's 3-Year EPS without NRI Growth Rate is ranked lower than
65% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. TBIO: -15.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TBIO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -58.5  Med: -10.85 Max: 179.5
Current: -15.7
-58.5
179.5
GuruFocus has detected 3 Warning Signs with Transgenomic Inc $TBIO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TBIO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with TBIO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:NAS:BIOP, NAS:HTGM, OTCPK:MDIT, OTCPK:MYAN, NAS:CBMX, NAS:BASI, OTCPK:BZYR, NAS:TEAR, NAS:ROKA, NAS:GENE, NAS:IDXG, OTCPK:MNLIF, OTCPK:MHTX, OTCPK:BTHCF, OTCPK:ILIU, NAS:ROSG, NAS:OPGN, OTCPK:MTST, OTCPK:LEDIF, OTCPK:LXXGF » details
Traded in other countries:TGKN.Germany,
Transgenomic Inc is a biotechnology company. It provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services.

Transgenomic Inc was incorporated in Delaware on March 6, 1997. The Company is a biotechnology company advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. Its operations are organized and reviewed by management along its product lines and presented in the following two complementary business segments: Laboratory Services and Genetic Assays and Platform. In Laboratory Services: its laboratories engaged in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. Its Patient Testing laboratories located in New Haven, Connecticut and Omaha, Nebraska are certified under the Clinical Laboratory Improvement Amendment ("CLIA") as high complexity laboratories and its Omaha facility is also accredited by the College of American Pathologists ("CAP"). Its laboratories employ genomic testing service technologies, including ICE COLD-PCR technology. ICE COLD-PCR is a proprietary platform technology that can be run in any laboratory with standard PCR technology and that enables detection of multiple unknown mutations from virtually any sample type including tissue biopsies, blood, cell-free DNA ("cfDNA") and circulating tumor cells ("CTCs") at levels greater than 1,000-fold higher than standard DNA sequencing techniques. In enetic Assays and Platforms: its proprietary product is the WAVE System, which has applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. It also distributes bioinstruments produced by other manufacturers ("OEM Equipment") through its sales and distribution network. The Company also distributes bioinstruments produced by other manufacturers ('OEM Equipment') through its sales and distribution network. Service contracts to maintain installed systems are sold and supported by its technical support personnel. The installed WAVE base and some OEM Equipment platforms generate a demand for consumables that are required for the continued operation of the bioinstruments. It develops, manufactures and sells these consumable products. In addition, it manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Competitors in these areas, among others, include Applied Biosystems, Qiagen, Roche, Sequenom and Illumina. Competition for some of its non-WAVE consumable products comes from numerous well-diversified life sciences reagent providers, including, among others, Invitrogen, Qiagen, Roche, Stratagene and Promega. The Company is subject to a variety of federal, state and municipal environmental and safety laws based on its use of hazardous materials in both manufacturing and research and development operations.

Ratios

vs
industry
vs
history
PS Ratio 8.79
TBIO's PS Ratio is ranked lower than
79% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. TBIO: 8.79 )
Ranked among companies with meaningful PS Ratio only.
TBIO' s PS Ratio Range Over the Past 10 Years
Min: 0.53  Med: 1.49 Max: 15.38
Current: 8.79
0.53
15.38
Current Ratio 0.05
TBIO's Current Ratio is ranked lower than
99% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. TBIO: 0.05 )
Ranked among companies with meaningful Current Ratio only.
TBIO' s Current Ratio Range Over the Past 10 Years
Min: 0.05  Med: 2.38 Max: 18.01
Current: 0.05
0.05
18.01
Quick Ratio 0.05
TBIO's Quick Ratio is ranked lower than
98% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. TBIO: 0.05 )
Ranked among companies with meaningful Quick Ratio only.
TBIO' s Quick Ratio Range Over the Past 10 Years
Min: 0.05  Med: 1.75 Max: 17.35
Current: 0.05
0.05
17.35
Days Inventory 6.04
TBIO's Days Inventory is ranked higher than
94% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.88 vs. TBIO: 6.04 )
Ranked among companies with meaningful Days Inventory only.
TBIO' s Days Inventory Range Over the Past 10 Years
Min: 4.7  Med: 110.37 Max: 332.02
Current: 6.04
4.7
332.02
Days Sales Outstanding 49.44
TBIO's Days Sales Outstanding is ranked higher than
68% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 61.18 vs. TBIO: 49.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
TBIO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.44  Med: 84.19 Max: 138.39
Current: 49.44
49.44
138.39
Days Payable 1.00
TBIO's Days Payable is ranked lower than
98% of the 135 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. TBIO: 1.00 )
Ranked among companies with meaningful Days Payable only.
TBIO' s Days Payable Range Over the Past 10 Years
Min: 1  Med: 47.74 Max: 711.37
Current: 1
1
711.37

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -32.60
TBIO's 3-Year Average Share Buyback Ratio is ranked lower than
78% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. TBIO: -32.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TBIO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -32.6  Med: -16.1 Max: 0
Current: -32.6
-32.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 5.70
TBIO's Price-to-Median-PS-Value is ranked lower than
99% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. TBIO: 5.70 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TBIO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48  Med: 1.04 Max: 11.79
Current: 5.7
0.48
11.79
Earnings Yield (Greenblatt) % -37.55
TBIO's Earnings Yield (Greenblatt) % is ranked lower than
84% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.78 vs. TBIO: -37.55 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TBIO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -38  Med: 2.5 Max: 3.4
Current: -37.55
-38
3.4

More Statistics

Revenue (TTM) (Mil) $1.33
EPS (TTM) $ -1.83
Beta-0.18
Short Percentage of Float15.30%
52-Week Range $0.15 - 1.59
Shares Outstanding (Mil)25.20
» More Articles for TBIO

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
TRANSGENOMIC INC Financials Feb 25 2017
TRANSGENOMIC INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant Feb 24 2017
TRANSGENOMIC INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing... Feb 21 2017
Transgenomic Provides Update on Its Planned Merger and Reports Change in Listing Status Feb 21 2017
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Transgenomic, Inc. -... Feb 13 2017
TRANSGENOMIC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Triggering Events... Jan 20 2017
TRANSGENOMIC INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial... Jan 19 2017
TRANSGENOMIC INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Triggering Events... Jan 17 2017
4 Companies That Beat Friday the 13th Jan 13 2017
Transgenomic Announces Leading Clinical Laboratory Services Provider LifeLabs Selects ICE COLD-PCR... Jan 12 2017
TRANSGENOMIC INC Files SEC form 8-K, Triggering Events That Accelerate or Increase a Direct... Jan 06 2017
Transgenomic, Inc. :TBIO-US: Earnings Analysis: Q3, 2016 By the Numbers : November 17, 2016 Nov 17 2016
TRANSGENOMIC INC Files SEC form 10-Q, Quarterly Report Nov 14 2016
TRANSGENOMIC INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing... Nov 02 2016
TRANSGENOMIC INC Files SEC form 8-K, Other Events Oct 13 2016
Transgenomic and Precipio Diagnostics Announce Planned Merger Oct 13 2016
Transgenomic and Precipio Diagnostics Announce Planned Merger Oct 12 2016
Transgenomic Adds New Distributors in China and India for its ICEme Kits that Enable Liquid Biopsy... Sep 29 2016
Transgenomic Adds New Distributors in China and India for Its ICEme Kits That Enable Liquid Biopsy... Sep 29 2016
TRANSGENOMIC INC Files SEC form 8-K, Change in Directors or Principal Officers Sep 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)